{"References": [{"title": "Combination cancer immunotherapy and new immunomodulatory targets", "authors": "Drew M. Pardoll", "journal": "Nature Reviews Drug Discovery", "year": "2012", "volumes": "11", "first page": "252", "last page": "264", "DOI": "10.1038/nrd3626"}, {"title": "Synergistic drug combinations tend to improve therapeutically relevant selectivity", "authors": "Lehar Joseph, Krueger Andrew S, Avery William, Heilbut Adrian M, Johansen Lisa M, Price E Roydon, Rickles Richard J, Short Glenn F, Staunton Donald E, Jin Xiaowei, Lee Margaret S, Zimmermann Grant R, Borisy Alexis A", "journal": "Nature Biotechnology", "year": "2009", "volumes": "27", "first page": "659", "last page": "666", "DOI": "10.1038/nbt.1549"}, {"title": "Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin", "authors": "Pluchino Kristen M, Hall Matthew D, Goldsborough Andrew S, Callaghan Rachel, Gottesman Michael M", "journal": "Biochemical Pharmacology", "year": "2012", "volumes": "83", "first page": "1472", "last page": "1479", "DOI": "10.1016/j.bcp.2012.02.014"}, {"title": "Combination approaches with immune-checkpoint blockade in cancer therapy", "authors": "Melero Ignacio, Berman David M, Aznar Maria Angela, Korman Alan J, Gracia Jose Luis Perez, Haanen John", "journal": "Nature Reviews Cancer", "year": "2015", "volumes": "15", "first page": "457", "last page": "472", "DOI": "10.1038/nrc3973"}, {"title": "Combination cancer therapy: rationale and clinical implications", "authors": "Bayat Mehrnoosh Rahmani, Mokhtari Reza Bayat, Baluch Narges, Homayouni Tahereh Sadeghian, Morgatskaya Ekaterina, Kumar Sushil, Das Bikul, Yeger Herman", "journal": "Future Oncology", "year": "2017", "volumes": "13", "first page": "765", "last page": "780", "DOI": "10.2217/fon-2016-0412"}, {"title": "Collateral sensitivity as a strategy against cancer multidrug resistance", "authors": "Pluchino Kristen M, Hall Matthew D, Goldsborough Andrew S, Callaghan Rachel, Gottesman Michael M", "journal": "Drug Resistance Updates", "year": "2012", "volumes": "15", "first page": "98", "last page": "105", "DOI": "10.1016/j.drup.2012.03.002"}, {"title": "Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy", "authors": "Ahn Soyeon, Jeong Dongjun, Oh Sang Jun, Ahn Jaewon, Baek Suk-Joo, Kim Seongyeol", "journal": "Journal of Immunology Research", "year": "2018", "volumes": "2018", "first page": "1", "last page": "11", "DOI": "10.1155/2018/4315679"}, {"title": "Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers", "authors": "Sun Chong, Fang Yuanbin, Yin Yuxin, Chen Xin, Ju Huaiqiang, Li Yiyi, Chen Xin, Vellano Christopher P, Jeong Kang Jin, Ng Pui Kei, Kundra Vikas, Estrella Jeannelyn S, Fleming Jason B, Hung Mien-Chie, Kopetz Scott, Lu Yiling", "journal": "Science Translational Medicine", "year": "2017", "volumes": "9", "first page": "eaal5148", "last page": "", "DOI": "10.1126/scitranslmed.aal5148"}, {"title": "Combination therapies with immune-checkpoint blockade in cancer treatment", "authors": "Mahoney Kelly M, Rennert Paul D, Freeman Gordon J", "journal": "Nature Reviews Drug Discovery", "year": "2015", "volumes": "14", "first page": "561", "last page": "584", "DOI": "10.1038/nrd4591"}, {"title": "Rational design of cancer drug combinations: An emerging concept in cancer therapy", "authors": "Al-Lazikani Bissan, Banerji Udai, Workman Paul", "journal": "Nature Reviews Cancer", "year": "2012", "volumes": "12", "first page": "801", "last page": "808", "DOI": "10.1038/nrc3364"}]}